中国医学创新2024，Vol.21Issue(36) ：18-22.DOI:10.3969/j.issn.1674-4985.2024.36.005

钠-葡萄糖协同转运蛋白2抑制剂对慢性心力衰竭合并肾功能不全患者心功能的影响

Effect of Sodium-glucose Cotransporter 2 Inhibitors on Cardiac Function in Patients with Chronic Heart Failure Combined with Renal Insufficiency

唐武生 万玉莹
中国医学创新2024，Vol.21Issue(36) ：18-22.DOI:10.3969/j.issn.1674-4985.2024.36.005
✕
  • 维普
  • 万方数据

钠-葡萄糖协同转运蛋白2抑制剂对慢性心力衰竭合并肾功能不全患者心功能的影响

Effect of Sodium-glucose Cotransporter 2 Inhibitors on Cardiac Function in Patients with Chronic Heart Failure Combined with Renal Insufficiency

唐武生 1万玉莹1
扫码查看

作者信息

  • 1. 芜湖市第二人民医院心血管内科 安徽 芜湖 241000
  • 折叠

摘要

目的:分析慢性心力衰竭(CHF)合并肾功能不全患者应用钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂的效果.方法:选取2021年1月—2023年12月芜湖市第二人民医院110例CHF合并肾功能不全患者为研究对象,按随机数字表法分为对照组(n=55)与研究组(n=55),分别接受常规治疗与联合SGLT-2抑制剂治疗.比较两组临床疗效、血清学相关指标、心功能指标及不良反应发生率.结果:研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05).同治疗前比较,两组治疗后半乳糖凝聚素3(Gal-3)、可溶性细胞间黏附因子-1(sICAM-1)、N末端B型利钠肽原(NT-proBNP)、血清心锚重复蛋白(CARP)、血清线粒体偶联因子-6(CF6)均降低,且研究组均低于对照组(P<0.05);研究组治疗后左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)均低于对照组,左心室射血分数(LVEF)、6 min步行距离(6MWD)均高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:针对CHF合并肾功能不全患者,采取SGLT-2抑制剂药物进行治疗,利于调节改善血清学指标异常与心功能,临床疗效确切,利于改善患者预后.

Abstract

Objective:To analyze the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with chronic heart failure (CHF) combined with renal insufficiency.Method:From January 2021 to December 2023,110 patients with CHF combined with renal insufficiency in Wuhu Second People's Hospital were selected as the study subjects.They were divided into control group (n=55) and study group (n=55) according to random number table method,and received conventional treatment or combined SGLT-2 inhibitor treatment,respectively.The clinical efficacy,serological indexes,cardiac function indexes and the incidence of adverse reactions were compared between the two groups.Result:The total effective rate of the study group was higher than that of the control group,the difference was statistically significant (P<0.05).Compared with those before treatment,galactoagglutinin-3 (Gal-3),soluble intercellular adhesion molecule-1 (sICAM-1),N-terminal pro-brain natriuretic peptide (NT-proBNP),serum cardiac ankyrin repeat protein (CARP) and serum mitochondrial coupling factor-6 (CF6) were decreased in both groups after treatment,those of the study group were lower than those of the control group (P<0.05).After treatment,the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) of the study group were lower than those of the control group,and the left ventricular ejection fraction (LVEF) and 6 min walking distance (6MWD) of the study group were higher than those of the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:SGLT-2 inhibitors are effective in regulating and improving serological indexes abnormalities and cardiac function in patients with CHF combined with renal insufficiency.The clinical efficacy is definite and it is beneficial for improving prognosis of patient.

关键词

慢性心力衰竭/肾功能不全/钠-葡萄糖协同转运蛋白2抑制剂/心功能

Key words

Chronic heart failure/Renal insufficiency/Sodium-glucose cotransporter 2 inhibitor/Heart function

引用本文复制引用

出版年

2024
中国医学创新
中国保健协会

中国医学创新

影响因子：1.706
ISSN：1674-4985
段落导航相关论文